Esperion stock rises after Japan approves cholesterol drug NEXLETOL
PositiveFinancial Markets

Esperion's stock has seen a significant rise following Japan's approval of its cholesterol-lowering drug, NEXLETOL. This approval is a major milestone for the company, as it opens up new market opportunities and enhances its credibility in the pharmaceutical industry. Investors are optimistic about the potential for increased sales and revenue, making this a noteworthy development in the healthcare sector.
— Curated by the World Pulse Now AI Editorial System